Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30476135 | 1.00 | KAT6A (0.46) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| SCHEMBL8379379 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| SCHEMBL8379679 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| SCHEMBL8378084 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| SCHEMBL8379382 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| SCHEMBL8380966 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| SCHEMBL8379211 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| Ammonia Solution, Strong SCHEMBL1158135 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| SCHEMBL8378138 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 | |
| SCHEMBL8376433 | 0.98 | KAT6A (0.44) | KAT6ATSHRSMN1; SMN2MYCHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 623 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119101231-A | Polyphenyl ether, prepreg containing polyphenyl ether, laminated board and printed circuit board | 盛虹(上海)新材料科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-118996422-A | Aluminum etching solution and preparation method and application thereof | 苏州惺忆新材料科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| EP-4306556-A1 | PROTIC IONIC LIQUID BASED ON DIALLYL AMMONIUM CATION AND RELATED MEMBRANE | Toyota Jidosha Kabushiki Kaisha (JP) | 2024-01-17 | — | — | EP | claimed |
| CN-116349679-A | Composite disinfection and sterilization method | 孙国明 | 2023-06-30 | — | — | CN | claimed |
| CN-116096112-A | Perovskite photoelectric device using fluorosulfonate interface modifier and preparation method thereof | 国能生物发电集团有限公司 | 2023-05-09 | — | — | CN | claimed |
| US-11621433-B2 | Proton exchange membrane material and methods of making the same | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2023-04-04 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| EP-3438108-B1 | PHENYL [A]INDOLE[2,3-G]QUINOLIZINE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-08-10 | — | — | EP | claimed |
| CN-112048580-B | Production method of mite-inhibiting antibacterial cow leather mat | 重庆隆发皮革制品有限责任公司 | 2021-07-30 | — | — | CN | claimed |
| CN-113061103-A | Preparation method of monofluoroolefin derivative | 中国科学院兰州化学物理研究所苏州研究院 | 2021-07-02 | — | — | CN | claimed |
| US-6447943-B1 | REDUCED FUEL CROSSOVER, REDUCED SENSITIVITY TO METAL ION IMPURITIES AND ABILITY TO OPERATE AT HIGHER TEMPERATURES; SOLID ELECTROLYTE MEMBRANE CONTAINS FREE ACID MOLECULES ENTRAPPED IN THE PORES OR BONDED TO THE INORGANIC POWDER | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 2002-09-10 | — | — | US | claimed |
| EP-0658552-B1 | Process for the preparation of alpha-tocopherol derivatives | EISAI CO LTD (JP) | 1999-03-31 | — | — | EP | claimed |
| US-5541329-A | Intermediates prepared in an asymmetric total synthesis of camptothecin analogs | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-30 | — | — | US | claimed |
| EP-0715618-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | claimed |
| US-5473104-A | Reacting sulfonated 3-hydroxybutyrolactone with trimethylamine , decyclization | NEUROCRINE BIOSCIENCES, INC. (US) | 1995-12-05 | — | — | US | claimed |
| EP-0656887-A1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-14 | — | — | EP | claimed |
| EP-0569168-A2 | Synthesis of alkyl tert-alkyl ether using haloacid-modified clay catalysts | TEXACO CHEMICAL INC. (US) | 1993-11-10 | — | — | EP | claimed |
| US-5214218-A | Montmorillonite clays | TEXACO CHEMICAL COMPANY (US) | 1993-05-25 | — | — | US | claimed |
| US-4820831-A | Process for preparing 4,4'-dihydroxydiphenyl sulfone having high purity | KONISHI CHEMICAL INDUSTRY CO., LTD. (JP) | 1989-04-11 | — | — | US | claimed |
| US-3992208-A | Photo-sensitive etchant and method for forming metal image using same | FUJI PHOTO FILM CO., LTD. (JA) | 1976-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | KAT6A 1495/4885TSHR 2716/4885SMN1; SMN2 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.